These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 16760802

  • 1. Nevirapine resistance viral mutations after repeat use of nevirapine for prevention of perinatal HIV transmission.
    Kuhn L, Sinkala M, Kankasa MP, Kasonde P, Thea DM, Aldrovandi GM.
    J Acquir Immune Defic Syndr; 2006 Jun; 42(2):260-2. PubMed ID: 16760802
    [No Abstract] [Full Text] [Related]

  • 2. Detection of HIV drug resistance mutations in pregnant women receiving single dose Nevirapine in south India.
    Jacob MS, Durairaj A, Vijayakumari J, Srijayanth P, Sivakumar MR.
    Indian J Pathol Microbiol; 2011 Jun; 54(2):359-61. PubMed ID: 21623090
    [Abstract] [Full Text] [Related]

  • 3. Characterization of nevirapine (NVP) resistance mutations and HIV type 1 subtype in women from Abidjan (Côte d'Ivoire) after NVP single-dose prophylaxis of HIV type 1 mother-to-child transmission.
    Toni TD, Masquelier B, Lazaro E, Dore-Mbami M, Ba-Gomis FO, Téa-Diop Y, Kouakou K, Diby J, Sia E, Soppi S, Essien S, Schrive MH, Pinson P, Chenal H, Fleury HJ.
    AIDS Res Hum Retroviruses; 2005 Dec; 21(12):1031-4. PubMed ID: 16379606
    [Abstract] [Full Text] [Related]

  • 4. Genetic linkage of nevirapine resistance mutations in HIV type 1 seven days after single-dose nevirapine.
    Jones D, Parkin N, Hudelson SE, Guay LA, Musoke P, Mmiro F, Jackson JB, Eshleman SH.
    AIDS Res Hum Retroviruses; 2005 Apr; 21(4):319-24. PubMed ID: 15943576
    [Abstract] [Full Text] [Related]

  • 5. [Drug resistance of HIV-1 as a result of using nevirapine for chemoprophylaxis of vertical viral transmission from HIV-infected mother to infant].
    Kazennova EV.
    Vopr Virusol; 2009 Apr; 54(1):45-8. PubMed ID: 19253732
    [Abstract] [Full Text] [Related]

  • 6. Intrapartum tenofovir and emtricitabine reduces low-concentration drug resistance selected by single-dose nevirapine for perinatal HIV prevention.
    Chi BH, Ellis GM, Chintu N, Cantrell RA, Sinkala M, Aldrovandi GM, Warrier R, Mbewe F, Nakamura K, Stringer EM, Frenkel LM, Stringer JS.
    AIDS Res Hum Retroviruses; 2009 Nov; 25(11):1099-106. PubMed ID: 19886836
    [Abstract] [Full Text] [Related]

  • 7. Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs. 6-8 weeks after single-dose nvp prophylaxis: HIVNET 012.
    Eshleman SH, Guay LA, Mwatha A, Cunningham SP, Brown ER, Musoke P, Mmiro F, Jackson JB.
    AIDS Res Hum Retroviruses; 2004 Jun; 20(6):595-9. PubMed ID: 15242535
    [Abstract] [Full Text] [Related]

  • 8. Minor drug-resistant HIV type-1 variants in breast milk and plasma of HIV type-1-infected Ugandan women after nevirapine single-dose prophylaxis.
    Pilger D, Hauser A, Kuecherer C, Mugenyi K, Kabasinguzi R, Somogyi S, Harms G, Kunz A.
    Antivir Ther; 2011 Jun; 16(1):109-13. PubMed ID: 21311114
    [Abstract] [Full Text] [Related]

  • 9. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).
    Eshleman SH, Mracna M, Guay LA, Deseyve M, Cunningham S, Mirochnick M, Musoke P, Fleming T, Glenn Fowler M, Mofenson LM, Mmiro F, Jackson JB.
    AIDS; 2001 Oct 19; 15(15):1951-7. PubMed ID: 11600822
    [Abstract] [Full Text] [Related]

  • 10. [Maternal and neonatal drug resistance].
    Bobkova MR.
    Vopr Virusol; 2011 Oct 19; 56(5):47-9. PubMed ID: 22171480
    [Abstract] [Full Text] [Related]

  • 11. Emergence of NNRTI drug resistance mutations after single-dose nevirapine exposure in HIV type 1 subtype C-infected infants in India.
    Kurle SN, Gangakhedkar RR, Sen S, Hayatnagarkar SS, Tripathy SP, Paranjape RS.
    AIDS Res Hum Retroviruses; 2007 May 19; 23(5):682-5. PubMed ID: 17530993
    [Abstract] [Full Text] [Related]

  • 12. Nevirapine-induced resistance is a problem.
    S Afr Med J; 2004 May 19; 94(5):338. PubMed ID: 15211947
    [No Abstract] [Full Text] [Related]

  • 13. HIVNET 012 and Petra.
    Wilfert CM.
    Lancet; 2004 Jan 17; 363(9404):244-5; author reply 245-6. PubMed ID: 14738805
    [No Abstract] [Full Text] [Related]

  • 14. Selection and persistence of viral resistance in HIV-infected children after exposure to single-dose nevirapine.
    Martinson NA, Morris L, Gray G, Moodley D, Pillay V, Cohen S, Dhlamini P, Puren A, Bhayroo S, Steyn J, McIntyre JA.
    J Acquir Immune Defic Syndr; 2007 Feb 01; 44(2):148-53. PubMed ID: 17117145
    [Abstract] [Full Text] [Related]

  • 15. Selection of resistance mutations in children receiving prophylaxis with lamivudine or nevirapine for the prevention of postnatal transmission of HIV.
    Giuliano M, Galluzzo CM, Germinario EA, Amici R, Bassani L, Dehò L, Vyankandondera J, Mmiro F, Okong P, Vella S.
    J Acquir Immune Defic Syndr; 2006 May 01; 42(1):131-3. PubMed ID: 16763503
    [No Abstract] [Full Text] [Related]

  • 16. Zidovudine with nevirapine for the prevention of HIV mother-to-child transmission reduces nevirapine resistance in mothers from the Western Cape, South Africa.
    van Zyl GU, Claassen M, Engelbrecht S, Laten JD, Cotton MF, Theron GB, Preiser W.
    J Med Virol; 2008 Jun 01; 80(6):942-6. PubMed ID: 18428139
    [Abstract] [Full Text] [Related]

  • 17. Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission.
    Flys TS, Donnell D, Mwatha A, Nakabiito C, Musoke P, Mmiro F, Jackson JB, Guay LA, Eshleman SH.
    J Infect Dis; 2007 Mar 01; 195(5):711-5. PubMed ID: 17262714
    [Abstract] [Full Text] [Related]

  • 18. Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and D.
    Flys TS, Chen S, Jones DC, Hoover DR, Church JD, Fiscus SA, Mwatha A, Guay LA, Mmiro F, Musoke P, Kumwenda N, Taha TE, Jackson JB, Eshleman SH.
    J Acquir Immune Defic Syndr; 2006 Aug 15; 42(5):610-3. PubMed ID: 16773030
    [Abstract] [Full Text] [Related]

  • 19. Transmission of human immunodeficiency virus type 1 nevirapine resistance mutation K103N from a treatment-naive mother to her child.
    Schmitz T, Kleinkauf N, Klempa B, Ringe H, Varnholt V, Grosch-Wörner I.
    Pediatr Infect Dis J; 2006 Mar 15; 25(3):275-6. PubMed ID: 16511398
    [Abstract] [Full Text] [Related]

  • 20. Resistance detected by pyrosequencing following zidovudine monotherapy for prevention of HIV-1 mother-to-child-transmission.
    Olson SC, Ngo-Giang-Huong N, Beck I, Deng W, Britto P, Shapiro DE, Bumgarner RE, Mullins JI, Van Dyke RB, Jourdain G, Frenkel LM.
    AIDS; 2015 Jul 31; 29(12):1467-71. PubMed ID: 26244386
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.